@im74ve.bsky.social and I are greatful for this recognition
#neuroprismcolloque.
A great pleasure to present our work on the 5-HT4R and discuss with colleagues and friends from @columbiapsych.bsky.social and other universities on #AI and psychiatry

@pharmaupsaclay.bsky.social @gsheads.bsky.social

3e édition du symposium sur la Santé Mentale.
@pharmaupsaclay

🗓️ Le Sport, bien plus qu'une activité physique
📅 jeudi 27 mars 2025
📌 @Maison des Arts du Plessis-Robinson

🗒️ Inscription gratuite mais obligatoire
➡️ lnkd.in/ekVHqcXX

En espérant vous voir nombreux
#sante #santementale #sport

Our latest paper entitled Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression is now available online. A great collaboration between #moodsteam and #shfj_cea

pubs.acs.org/doi/full/10....

Happy to talk with my colleagues Pr Delphine Joseph @delfjoseph.bsky.social on the interest of 5HT4 ligands to treat anxiety during the scientific day of @gsheads.bsky.social @im74ve.bsky.social

#MOODS_Inserm @univparissaclay.bsky.social
@pharmaupsaclay.bsky.social

Lancement des 4eme journées scientifiques GS HeaDS en partenariat avec OI HEALTHI par Pr Delphine Joseph, Directrice GS et Marc Pallardy, Doyen UFR pharmacie
@pharmaupsaclay.bsky.social @univparissaclay.bsky.social @delfjoseph.bsky.social @gsheads.bsky.social

Great time at #encephale2025 talking about the pipelines to treat anxiety and depression with a special focus on serotonin type 4 receptor
@gsheads.bsky.social
@pharmaupsaclay.bsky.social

The Moods preclinical teams @univparissaclay.bsky.social
🧬🧪

When 5-HT4R meets NMDA receptor.
Congrats @brikchen.bsky.social and @drchristineannd.bsky.social for this great work. #acnp @npp-journal.bsky.social @im74ve.bsky.social and I are really happy to be part of this beautiful story